Oncolytics Biotech (TSX:ONC) EBIT per Share : C$-0.46 (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech EBIT per Share?

Oncolytics Biotech's EBIT per Share for the three months ended in Dec. 2024 was C$-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was C$-0.46.

During the past 3 years, the average EBIT per Share Growth Rate was 2.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 11.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oncolytics Biotech's EBIT per Share or its related term are showing as below:

TSX:ONC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -47.9 Med: 3.7 Max: 36.5
Current: 2.3

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oncolytics Biotech was 36.50% per year. The lowest was -47.90% per year. And the median was 3.70% per year.

TSX:ONC's 3-Year EBIT Growth Rate is ranked worse than
56.97% of 1234 companies
in the Biotechnology industry
Industry Median: 7.95 vs TSX:ONC: 2.30

Oncolytics Biotech's EBIT for the three months ended in Dec. 2024 was C$-8.44 Mil.

Oncolytics Biotech EBIT per Share Historical Data

The historical data trend for Oncolytics Biotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech EBIT per Share Chart

Oncolytics Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.63

-0.49

-0.46

-0.50

-0.46

Oncolytics Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.12	-0.12	-0.10	-0.13	-0.11

Oncolytics Biotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oncolytics Biotech's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-34.982	/	76.483
=	-0.46

Oncolytics Biotech's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.437	/	77.570
=	-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.46

Oncolytics Biotech (TSX:ONC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Oncolytics Biotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ONCY:USA

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Executives